Previous Close | 3.6300 |
Open | 3.5000 |
Bid | 0.0000 x 1200 |
Ask | 3.9600 x 3000 |
Day's Range | 3.5000 - 3.9800 |
52 Week Range | 0.4600 - 4.0900 |
Volume | |
Avg. Volume | 1,449,100 |
Market Cap | 151.261M |
Beta (5Y Monthly) | 0.21 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2810 |
Earnings Date | Aug 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for TRVI
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced that management will host a conference call and live audio webcast on Thursday, August 11, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the second quarter ended June 30
Many investors are currently fearful of the stock market downtrend and aren’t as active in the market. Moreover, the risk of a recession has also discouraged any investments in the stock market. However, penny stocks with excellent growth prospects offer a unique opportunity for long-term profits, especially in the current dip. 7 Best AI Stocks to Buy Now Nonetheless, penny stocks can be risky in the short term due to their low market capitalization and trading volume. However, companies with so
If you want to know who really controls Trevi Therapeutics, Inc. ( NASDAQ:TRVI ), then you'll have to look at the...